GC Therapeutics (GCTx), a pioneering biotechnology company advancing groundbreaking iPSC-based cell therapies, today announced the appointment of two industry leaders to its executive team.

TFome™, the world’s first “plug-and-play” iPSC cellular programming platform, streamlines development and accelerates pipeline of potential best-in-class cell therapies across diverse therapeutic areas 

Amgen awarded GCTx Golden Tickets, which provide lab space at Lab Central (Cambridge, MA) and access to Amgen’s expertise in drug development

YEi Start in France is an accelerator program for science-based startup companies